Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents.
Level 5 - mechanism / opinion, no new human data
in vitro bench research
PubMed 26909689 · doi:10.1055/s-0035-1569405
What was done
Researchers examined the mechanism by which uric acid affects endothelial function using cultured human umbilical vein endothelial cells (HUVECs). They assessed the expression of four uric acid transporters (URATv1, ABCG2, MRP4, and MCT9) and measured nitric oxide (NO) production and endothelial nitric oxide synthase (eNOS) protein phosphorylation after exposing cells to urate (7 mg/dL for 24 hours), with or without pretreatment using urate-lowering agents (benzbromarone, losartan, or irbesartan).
What was found
HUVECs expressed URATv1, ABCG2, MRP4, and MCT9. Exposure to 7 mg/dL urate for 24 hours significantly reduced NO production and induced dephosphorylation of eNOS (no exact numerical values or effect sizes were reported in the abstract). Pretreatment with benzbromarone, losartan, or irbesartan normalized NO production and prevented eNOS dephosphorylation.
Why it matters
This study outlines a cellular mechanism linking hyperuricemia to impaired endothelial NO synthesis via uric acid transporters and eNOS dephosphorylation, showing that certain urate-lowering agents and ARBs can directly preserve endothelial NO production.
Limits
This was an in vitro cell culture study, which cannot fully replicate human in vivo vascular conditions. The abstract reports no quantitative values, sample sizes (number of biological replicates), or specific effect sizes.
Cited by
- supports Treating endothelial cells with uric acid blocks nitric oxide production.